Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232